

HETEROCYCLES, Vol. 78, No. 8, 2009, pp. 2041 - 2052. © The Japan Institute of Heterocyclic Chemistry
Received, 25th March, 2009, Accepted, 14th April, 2009, Published online, 17th April, 2009.
DOI: 10.3987/COM-09-11716

SYNTHESIS OF ARYLTETRALIN TYPE 2-AZALIGNANS USING SCHÖLLKOPF'S BISLACTIM-ETHER METHODOLOGY

Yoshihide Usami,^{a,*} Masao Arimoto,^{a,*} Kiyomi Kobayashi,^a Mikiko Honjou,^a
Masako Yamanaka,^a Misaki Miyao,^a Hayato Ichikawa,^a Kenneth F. Bastow,^b
and Kuo-Hsiung Lee^c

^a Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki
569-1094, Osaka, Japan; E-mail: usami@gly.oups.ac.jp

^b Division of Medicinal Chemistry and Natural Products, School of Pharmacy,
University of North Carolina, Chapel Hill, NC 27599-7360, USA

^c Natural Products Research Laboratories, School of Pharmacy, University of
North Carolina, Chapel Hill, NC 27599-7360, USA

Abstract – Synthesis of (1*S*,3*R*)-2-aza-4-deoxypodophyllotoxin has been accomplished in 6 steps using Schöllkopf's bislactim-ether methodology in 12% total yield. Bislactim-ether, which was originally prepared from commercially available L-valine and glycine, was used as the starting material. Our synthetic route was allied to easy access to aryltetralin type 2-azalignan analogues. Synthesized 2-azalignans were tested for *in vitro* anticancer activity using a panel of human cancer cell lines. Both of two (1*S*)-diastereomers (**9a** and **9b**) of 2-aza-4-deoxypodophyllotoxin showed significant activity against human cancer cell lines: A-549 (lung), HTC-8 (ileocecal), and MCF-7 (breast cancer).

INTRODUCTION

Lignans are a large family of naturally occurring compounds constructed by oxidative dimerization of phenylpropane (C₆-C₃) units.¹ Podophyllotoxin (**1**), one of the most well known toxic lignans, was originally isolated from *Podophyllum* sp. that are widely distributed in nature. Because of its extremely strong tubulin-protein binding activity, which is responsible for its ability to inhibit the formation of microtubules, **1** could not be used as a clinical drug.^{2,3} Nevertheless, it was further developed to yield such popular anticancer drugs as etoposide (**3**) and teniposide (**4**) in the 80s. The mechanism of the anticancer activity is not the inhibition of microtubule formation as observed in **1** but the inhibition of topoisomerase II.^{4,5} Another candidate for anti-cancer drug currently on phase II clinical trials is GL-331 (**5**) developed by Lee and co-workers.⁶ Structures of them were shown in Figure 1.





Figure 1. Structures of natural aryltetralin lignans and their analogues

In our continuing studies of the isolation or the synthetic aspects of podophyllotoxin-related lignans including 4-dexy-podophyllotoxin (2), focusing on the Okinawan higher plant *Hernandia ovigera* L. that is distributed in tropical regions in Japan,^{7,8,9} we were also interested in the asymmetric synthesis of artificial aza-lignanes,¹⁰ which have gained significant attention from the end of the 1980s and are thought to be promising candidates for anticancer drug.¹¹⁻²⁵ In 1989 the synthesis of 2-azapodophyllotoxin was reported by Pearce at the first time.¹⁸ Then Vandewalle and co-workers reported the synthesis of 2-aza-4-deoxy-podophyllotoxin (9a) using the Bischler-Napieralski method.^{19,20} Expensive L- or D-DOPA was used as chiral starting material in the literature. Another successful asymmetric synthesis of (1*R*,3*S*)-9a was reported by Koga and co-workers.^{21,22} A series of studies of Koga group elucidated that 9a exhibited potent cytotoxicity against KB cells by inhibiting microtubule assembly but the corresponding ortho-quinone had potent DNA topoisomerase II inhibiting activity.^{23,24} However, their optically active amino acid starting material must be prepared by diastereomeric salt resolution between synthesized racemic amino acid derivative and natural cinchonine or by enzymatic kinetic resolution using takadiastase to the same racemic amino acid derivative²⁶ in their elegant synthetic route. Another recent study of synthesis of azapodophyllotoxin analogues also started from L-DOPA.²⁷ Herein we report the modified synthesis of (1*S*,3*R*)-2-aza-4-deoxy-podophyllotoxin 9a from chiral starting material prepared from inexpensive L-valine and glycine via Schöllkopf's bislactim-ether methodology.²⁸ 2-Aza-lignans 10 and 11 as analogues of naturally occurring bursehemin^{29,31,32,33,34} (6) and

polygamains^{35,36,37} (**7**, **8**) were also synthesized. Synthesized 2-azalignans in this study were applied to biological assay against human cancer cell lines. Bioactivity of (1*S*,3*R*)-**9a** has not been satisfactory evaluated since (1*S*)-stereoisomers showed less cytotoxicity than (1*R*)-stereoisomers in earlier bioassay against KB cell.²²

RESULTS AND DISCUSSION

Schöllkopf's dimethyl-bislactim ether **12** was prepared from *L*-valine and glycine along a known method.²⁸ The anion prepared from the bislactim-ether by treatment with *n*-BuLi in dry THF at $-78\text{ }^{\circ}\text{C}$ was reacted with piperonylbromide to give product **13** in 61% yield. The diastereomeric excess of this reaction was estimated to be 95% from $^1\text{H-NMR}$ analysis. The relative configuration of major diastereoisomer **13** was supported by the observation of the shift of the signal of H-3 at δ 3.37 ppm to the higher field in the $^1\text{H-NMR}$ spectrum, which was caused by the anisotropic effect of the cis-rearranged aromatic ring. Purified major diastereomer **13** was hydrolyzed into the methyl ester of chiral amino acid **14**,^{38,39,40} which was so unstable that was transformed into the corresponding dimer **15**⁴¹ when it was left at rt, as shown in Figure 2, during storage at room temperature. Thus, hydrolyzed crude **14** was treated immediately with CbzCl to form corresponding *N*-Cbz protected methyl ester **16** in 78% yield in 2 steps.



Scheme 1. Synthesis of 2-azalignans 9–11

Protected **16** was reduced with $\text{LiAlH}(\text{O}^t\text{Bu})_3$ into alcohol **17** in 68% yield, which was then converted into oxazolidone **18** by treatment with NaH in 82% yield. This synthesis was completed by a Pictet-Spengler condensation between **18** and 3,4,5-trimethoxybenzaldehyde using the same condition as the literature²² affording (1*S*,3*R*)-2-aza-4-deoxypodophyllotoxin **9** in 46% yield with its diastereomer (2%) in our hand. Total yield of this synthesis was 12% in 6 steps from **12**.




Figure 2. Structure of **15**

The relative stereochemistry of purified major diastereomer **9a** was confirmed by NOESY analysis where cross peaks were observed between H-2/aromatic protons in the 3,4,5-trimethoxyphenyl group, H-1/H-8, and H-4a,b/H-5. The absolute configuration of the synthesized compound was confirmed as illustrated in Scheme 1 on the basis of the fact that its specific rotation had an opposite sign compared with that of known (1*R*,3*S*)-2-aza-4-deoxypodophyllotoxin. Another condition¹⁶ was examined in order to reduce minor product resulting lower yield of **9a** (entry 2 in Table 1). Furthermore this synthetic route was applied to some 2-azalignane analogues of natural lignans **6–8** as described in entry 3–5 in Table 1.

Table 1. Cyclization to 2-Azalignans from **18**

entry	reagent	condition	product (yield)			recovery
1	3,4,5-trimethoxybenzaldehyde	H_2SO_4 , CH_2Cl_2 , rt ²²	9a (46%)	9b (2%)	18 (5%)	
2	3,4,5-trimethoxybenzaldehyde	$\text{CF}_3\text{SO}_3\text{H}$, CH_2Cl_2 , 5°C, 24hr	9a (4%)	9b (0%)	18 (62%)	
3	3,4-dimethoxybenzaldehyde	$\text{CF}_3\text{SO}_3\text{H}$, CH_2Cl_2 , 5°C, 24hr	10a (21%)	10b (2%)	18 (23%)	
4	2,5-dimethoxybenzaldehyde	$\text{CF}_3\text{SO}_3\text{H}$, CH_2Cl_2 , rt, 24hr	10c (34%)		18 (12%)	
5	piperonal	$\text{CF}_3\text{SO}_3\text{H}$, CH_2Cl_2 , 5°C, 24hr	11a (52%)	11b (2%)	18 (24%)	

Synthesized compounds in this study were applied to cytotoxicity test against three kinds of human cancer cell lines, which are A-549 (lung), HTC-8 (ileocecal), and MCF-7 (breast cancer). Results were summarized in Table 2.

2-Azalignans **9a** and **9b** showed strong cytotoxicity without selectivity. Others **10a**, **10c**, and **11b** also showed weak cytotoxicity whereas **10b** and **11a** were not cytotoxic. This result suggested that what

effected to cytotoxicity is not relative chemistry of 2-azalignans but substituents on the phenyl group at C-1.

Table 2. Cytotoxic Activity of 2-Azalignans against Human Tumor Cell Lines

Compound	ED ₅₀ * (μg/mL)		
	A549	HCT-8	MCF-7
9a	0.14	0.42	0.64
9b	0.06	0.07	0.09
10a	8.6	8.3	7.5
10b	>10	>10	>10
10c	3.15	6.8	8.4
11a	>10 (47)	NA	NA
11b	4.9	>10 (40)	NA

* ED₅₀ in μg/mL for 3 days continuous exposure-mean of two independent determinations

In conclusion, we have developed a facile synthetic route of (1*S*,3*R*)-**9a** *via* chiral artificial amino acid derivative **13** prepared using Schöllkopf's bislactim-ether methodology. The total yield of this synthesis from bislactim-ether **12** was 12% in 6 steps. Some applications of synthesizing 2-azalignans were also demonstrated to show our method provide easy and low-cost synthetic access. Among the synthesized compounds, **9a** showed significant cytotoxicity and **9b** showed more potent activity against human cancer cell lines: A549, HCT-8, and MCF-7.

EXPERIMENTAL

General. IR spectra were obtained with a Perkin Elmer FT-IR spectrometer 1720X or a JEOL FT/IR-680 Plus spectrometer. HRMS were determined using a Hitachi 4000H mass spectrometer and a JEOL JMS-700 (2) mass spectrometer. NMR spectra were recorded at 27 °C on Varian UNITY INOVA-500 and Mercury-3000 spectrometers in CDCl₃ with tetramethylsilane (TMS) as internal reference. Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. Specific rotations were measured using a JASCO model DIP1000 digital polarimeter. Liquid column chromatography was conducted over silica gel (SILICYCLE, Silia Flash F60, mesh 230–400). Analytical TLC was performed on precoated Merck glass (Silica gel 60), and compounds were viewed by dipping the plates in an ethanol solution of phosphomolybdic acid, followed by heating. Dry THF was distilled over sodium-benzophenone ketyl under argon atmosphere.

(3*S*,6*S*)-3,6-Dihydro-3-isopropyl-2,5-dimethoxy-6-(3,4-methylenedioxy)benzylpyrazine **13**

To a solution of **12** (3.06 g, 16.6 mmol) in dry THF (38 mL) was added *n*-BuLi (1.5 M, 12.2 mL, 18.3 mmol) at –78 °C with stirring under nitrogen atmosphere. After 15 min, a solution of piperonylbromide

(4.25 g, 20.0 mmol) in THF (38 mL) was added to the reaction flask and the reaction mixture was stirred for 24 h to allow reaction to proceed at rt. The reaction mixture was treated with aq. NH_4Cl , evaporated to reduce organic solvent, and extracted with Et_2O . The organic layer was dried over MgSO_4 , filtered, and evaporated under reduced pressure to afford the crude product, which was purified by silica gel column chromatography (hexane:EtOAc = 8:1) to give **13** in 71% yield (3.78 g). The product ratio was determined to be 95% d.e. from the $^1\text{H-NMR}$ spectrum of the crude product. **13**: Colorless crystals: mp 64–69 °C; $[\alpha]_{\text{D}}^{25}$ –84.9 (c 0.05, EtOH); IR (KBr) ν_{max} 1700 (C=N), 1510 (C=C), 1500 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 0.55 (3H, d, $J = 6.8$ Hz, *iPr-CH*₃), 0.90 (3H, d, $J = 6.8$ Hz, *iPr-CH*₃), 2.10 (1H, sept d, $J = 6.8, 3.8$ Hz, 3-*CH*(CH_3)₂), 2.94 (2H, m, -*CH*₂Ph), 3.37 (1H, t, $J = 3.3$ Hz, H-3), 3.62 (3H, s, OMe), 3.64 (3H, s, OMe), 4.20 (1H, m, H-6), 5.82 (2H, m, -*OCH*₂*O*-), 6.48 (1H, br d, $J = 7.9$ Hz, aromatic H), 6.53 (1H, br s, aromatic H), 6.59 (1H, d, $J = 7.9$ Hz, aromatic H); $^{13}\text{C-NMR}$ (CDCl_3) δ 16.9, 19.4, 31.6, 39.9, 52.3, 52.6, 56.7, 60.4, 100.5, 107.5, 110.1, 122.6, 130.6, 145.5, 146.5, 161.7, 163.2; MS m/z 319 (M^+); *Anal.* Calcd for $\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}_4$: C, 64.13; H, 6.97; N, 8.80. Found: C, 64.20; H, 6.97; N, 8.83.

(2R)-Methyl N-Cbz-2-amino-2-(3,4-methylenedioxy)benzylethanoate 16

To a solution of **13** (3.78 g, 11.9 mmol) in MeOH (78.7 mL) was added 0.25 N HCl aq. (104.4 mL, 26.1 mmol) at rt with stirring. After 2 days, MeOH was removed under reduced pressure to afford an aq. solution that was extracted with CHCl_3 . After adjusting pH to 8–10 by the addition of aq. NH_3 , the water layer was extracted with CH_2Cl_2 three times. The organic layers were combined and evaporated to afford crude residue **14**, which was used in the next reaction without purification. To a reaction mixture of **14** and CbzCl (3.73 mL, 26.1 mmol) in H_2O (37.2 mL) was added gradually K_2CO_3 (8.20 g, 59.3 mmol) at rt. After stirring for 24 h, the reaction mixture was acidified with conc. HCl and extracted with CHCl_3 . The organic layer was washed with brine, dried over MgSO_4 , filtered, and evaporated to give a crude residue, which was purified by silica gel column chromatography (EtOAc:hexane = 3:1) to give **16** in 84% yield (3.57 g). **(2R)-Methyl 2-amino-2-(3,4-methylenedioxy)benzylethanoate 15**: Colorless oil: $[\alpha]_{\text{D}}^{25}$ –26.3 (c 0.02, CHCl_3); IR (liquid film) ν_{max} 3308 (N-H), 1737 (C=O), 1502 (C=C), 1490 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.06 (2H, br s, NH_2), 2.75 (1H, dd, $J = 13.7, 7.7$ Hz, ArCHaHb-), 2.96 (1H, dd, $J = 13.7, 5.1$ Hz, ArCHaHb-), 3.66 (3H, s, COOCH_3), 3.66 (1H, overlapped, -*CH*(COOMe) NH_2), 6.59 (1H, dd, $J = 7.8, 1.5$ Hz, Ar-H), 6.67 (1H, d, $J = 1.5$ Hz, Ar-H), 6.67 (1H, d, $J = 7.8$ Hz, Ar-H); $^{13}\text{C-NMR}$ (CDCl_3) δ 40.5, 52.2, 58.9, 100.7, 108.1, 109.2, 122.0, 130.0, 146.0, 147.2, 174.2; HREIMS m/z calcd for $\text{C}_{11}\text{H}_{13}\text{NO}_4$ (M^+) 223.0845, found, 223.0840; *Anal.* Calcd for $\text{C}_{19}\text{H}_{19}\text{NO}_6 \cdot 1/2\text{H}_2\text{O}$: C, 61.55; H, 4.95; N, 7.15. Found: C, 61.84; H, 4.74; N, 7.32. **16**: Colorless crystals: mp 93–95 °C; $[\alpha]_{\text{D}}^{25}$ +11.9 (c 0.02, EtOH); IR (KBr) ν_{max} 1690 (C=O), 1643 (C=C), 1470 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.94 (1H, dd, $J = 14.0, 5.7$ Hz, piperonyl-CHaHb-), 2.97 (1H, dd, $J = 14.0, 5.3$ Hz,

piperonyl-*CHaHb*-), 3.66 (3H, s, COOCH₃), 4.20 (1H, m, H-6), 4.55 (1H, ddd, $J = 8.0, 5.7, 5.3$ Hz, NHCHCOOMe(piperonyl)), 5.02 (1H, d, $J = 12.3$ Hz, Ph-*CHaHb*-O), 5.03 (1H, d, $J = 12.3$ Hz, Ph-*CHaHb*-O), 5.85 (2H, m, -OCH₂O-), 6.46 (1H, dd, $J = 7.9, 1.8$ Hz, aromatic H), 6.51 (1H, d, $J = 1.8$ Hz, aromatic H), 6.63 (1H, d, $J = 7.9$ Hz, aromatic H), 7.20-7.40 (5H, m, Ph H); ¹³C-NMR (CDCl₃) δ 38.1, 52.5, 55.0, 67.1, 100.8, 108.1, 109.2, 122.0, 127.7, 127.8, 128.1, 128.8, 135.7, 146.2, 147.2, 155.0, 171.2; MS m/z 358 (M⁺); *Anal.* Calcd for C₁₉H₁₉NO₆: C, 63.86; H, 5.36; N, 3.92. Found: C, 63.43; H, 5.40; N, 3.93.

(2*R*)-*N*-Cbz-2-Amino-2-(3,4-methylenedioxy)benzylethanol **17**

To a suspension of LiAlH(O*t*Bu)₃ in Et₂O (200 mL), which was prepared by reacting LiAlH₄ (0.95 g, 25 mmol) with *t*BuOH (7.17 mL, 75 mmol), was added a solution of **16** in Et₂O (20 mL) dropwise under nitrogen atmosphere. After stirring overnight at rt, the reaction mixture was treated with 10% H₂SO₄ aq. and extracted with Et₂O. The organic layer was washed with brine, dried over MgSO₄, filtered, and evaporated to give a crude residue, which was purified by silica gel column chromatography (EtOAc: CHCl₃ = 1:9) to give **17** (2.25g, 68%). **17**: Colorless crystals: mp 86–87 °C; $[\alpha]_D^{25} +44.6$ (c 0.02, EtOH); IR (KBr) ν_{\max} 3621 (OH), 3433 (NH), 1699 (C=O), 1610 (C=C), 1515 (C=C) cm⁻¹; ¹H-NMR (CDCl₃) δ 2.70 (2H, d, $J = 7$ Hz, piperonyl-CH₂), 3.49 (1H, dd, $J = 10.6, 4.7$ Hz, -*CHaHb*-OH), 3.59 (1H, dd, $J = 10.6, 3.1$ Hz, -*CHaHb*-OH), 3.79 (1H, m, NHCHCH₂OH(piperonyl)), 4.20 (1H, m, H-6), 4.79 (1H, br s, NH), 5.00 (2H, s, -OCH₂Ph), 5.85 (2H, s, -OCH₂O-), 5.85 (2H, m, -OCH₂O-), 6.56 (1H, br d, $J = 7.9$ Hz, aromatic H), 6.63 (1H, br s, aromatic H), 6.65 (1H, d, $J = 7.9$ Hz, aromatic H), 7.20-7.40 (5H, m, Ph-H); ¹³C-NMR (CDCl₃) δ 37.3, 54.4, 63.9, 69.9, 100.7, 108.1, 109.3, 121.9, 127.7, 127.8, 128.1, 130.8, 135.8, 145.7, 147.2, 155.9; MS m/z 330 (M⁺); *Anal.* Calcd for C₁₈H₁₉NO₅: C, 65.64; H, 5.82; N, 4.25. Found: C, 65.61; H, 5.79; N, 4.25.

(4*R*)-4-Piperonyl-1,3-oxazolidin-2-one **18**

To a suspension of NaH (0.32 g, 7.98 mmol) in dry THF (66.5 mL) was added **17** (2.19 g, 6.65 mmol) in THF (5 mL) at 0 °C. After stirring for 4 h, the reaction mixture was quenched with ice water, then THF was removed under reduced pressure to afford a crude residue. After extraction with CHCl₃, the organic layer was washed with brine, dried over MgSO₄, filtered, and evaporated to give a crude residue, which was purified by silica gel column chromatography (EtOAc: CHCl₃ = 1:1) to give **18** in 92% yield (1.36 g). **18**: Colorless crystals: mp 96–98 °C; $[\alpha]_D^{25} +55.0$ (c 1.29, CHCl₃); IR (KBr) ν_{\max} 3450 (NH), 1761 (C=O), 1618 (C=C), 1510 (C=C), 1500 (C=C) cm⁻¹; ¹H-NMR (CDCl₃) δ 2.75 (1H, dd, $J = 13.7, 6.4$ Hz, 4-Hb), 2.80 (1H, dd, $J = 13.7, 7.0$ Hz, 4-Ha), 4.01 (1H, dddd, $J = 8.6, 7.2, 6.4, 5.5$ Hz, H-3), 4.12 (1H, dd, $J = 8.6, 5.5$ Hz, -CHCHaHbCOO-), 4.41 (1H, t, $J = 8.6$ Hz, -CHCHaHbCOO-), 5.85 (1H, s, H-1), 5.93 (2H, s, -OCH₂O-), 5.99 (1H, s, NH), 6.61 (1H, dd, $J = 7.7, 1.6$ Hz, Ar-H), 6.64 (1H, d, $J = 1.6$ Hz,

Ar-H), 6.75 (1H, d, $J = 7.7$ Hz, Ar-H); ^{13}C -NMR (CDCl_3) δ 41.3, 54.0, 69.5, 100.9, 108.4, 108.9, 121.7, 129.1, 146.2, 147.5, 158.9; MS m/z 220 (M^+); *Anal.* Calcd for $\text{C}_{11}\text{H}_{11}\text{NO}_4$: C, 59.72; H, 5.01; N, 6.33. Found: C, 59.76; H, 5.02; N, 6.32.

Synthesis of 2-Aza-lignans (Scheme 1, Table 1)

Typical procedure: To a solution of **18** (33.8 mg, 0.15 mmol) and piperonal (25.2 mg, 0.15 mmol) in CH_2Cl_2 (2 mL) was added trifluoromethanesulfonic acid (25.6 μL , 0.29 mmol) at 5 °C. After stirring for 24 h, the reaction mixture was quenched with aq. NaHCO_3 , and extracted with CH_2Cl_2 . The organic layer was washed with brine, dried over MgSO_4 , filtered, and evaporated to give a crude residue, which was purified by preparative TLC (EtOAc: $\text{CH}_2\text{Cl}_2 = 1:3$) to give **11a** (25.6 mg, 52% yield) and **11b** (0.8 mg, 2% yield) with recovery of **18** (8.3 mg, 24%). *Diastereomers **10a** and **10b** were finally separated by preparative TLC using solvent system of 5% MeOH in CH_2Cl_2 .

(1S,3R)-2-Aza-4-deoxypodophyllotoxin 9a: Colorless needles: mp 200–201 °C; $[\alpha]_{\text{D}}^{25} +160.0$ (c 0.05, CH_3Cl); IR (KBr) ν_{max} 1734 (C=O), 1589 (C=C) cm^{-1} ; ^1H -NMR (CDCl_3) δ 2.88 (1H, dd, $J = 15.6, 10.5$ Hz, 4-Hb), 2.93 (1H, dd, $J = 15.6, 5.0$ Hz, 4-Ha), 3.80 (6H, s, Ar-OCH₃), 3.84 (3H, s, Ar-OCH₃), 4.04 (1H, dddd, $J = 10.5, 8.4, 5.0, 4.3$ Hz, H-3), 4.11 (1H, dd, $J = 8.4, 4.3$ Hz, -CHCHaHbCOO-), 4.48 (1H, t, $J = 8.4$ Hz, -CHCHaHbCOO-), 5.85 (1H, s, H-1), 5.93 (1H, d, $J = 1.5$ Hz, -OCHaHbO-), 5.96 (1H, d, $J = 1.5$ Hz, -OCHaHbO-), 6.46 (1H, s, H-8), 6.47 (2H, s, 1-Ar-H), 6.64 (1H, s, H-5); ^{13}C -NMR (CDCl_3) δ 34.7, 48.3, 56.4, 56.6, 60.9, 68.4, 101.0, 105.6, 108.0, 108.2, 125.2, 126.3, 137.1, 137.3, 146.2, 146.6, 152.7, 155.9; HREIMS m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_1\text{O}_2$ (M^+) 399.1318, found, 399.1312.

(1R,3R)-2-Aza-4-deoxypodophyllotoxin 9b: Colorless crystals: mp 239–243 °C; $[\alpha]_{\text{D}}^{22} +49.5$ (c 0.02, CH_3Cl); IR (KBr) ν_{max} 1761 (C=O), 1593 (C=C), 1486 (C=C) cm^{-1} ; ^1H -NMR (CDCl_3) δ 2.96 (1H, dd, $J = 14.9, 4.1$ Hz, 4-Hb), 3.01 (1H, dd, $J = 14.9, 10.2$ Hz, 4-Ha), 3.80 (3H, s, Ar-OCH₃), 3.82 (6H, s, Ar-OCH₃), 4.05 (1H, dd, $J = 11.0, 7.8$ Hz, -CHCHaHbCOO-), 4.10 (1H, m, H-3), 4.56 (1H, dd, $J = 7.8, 6.5$ Hz, -CHCHaHbCOO-), 5.49 (1H, s, H-1), 5.90 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 5.94 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 6.50 (2H, s, Ar-H-2'), 6.53 (1H, s, H-8), 6.62 (1H, s, H-5); ^{13}C -NMR (CDCl_3) δ 34.2 (t), 54.6 (d), 56.1 (q), 59.7 (d), 60.8(q), 68.3 (d), 101.3 (t), 104.7 (d), 108.0 (d), 108.6 (d), 124.2 (s), 130.0 (s), 137.5 (s), 138.0 (s), 146.8 (s), 147.2 (s), 153.2 (s), 156.8 (s); HRMS m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_1\text{O}_7$ (M^+) 369.1218, found 399.1317.

(1S,3R)-2-Azabursehernin 10a: Colorless crystals: mp 225–228 °C; $[\alpha]_{\text{D}}^{25} +71.8$ (c 1.00, CH_3Cl); IR (KBr) ν_{max} 1729 (C=O), 1503, 1488 (C=C) cm^{-1} ; ^1H -NMR (CDCl_3) δ 2.88 (1H, dd, $J = 15.5, 10.3$ Hz, 4-Hb), 2.92 (1H, dd, $J = 15.5, 5.0$ Hz, 4-Ha), 3.85 (3H, s, Ar-OCH₃), 3.86 (3H, s, Ar-OCH₃), 4.02 (1H, dddd, $J = 10.3, 8.2, 5.0, 4.3$ Hz, H-3), 4.10 (1H, dd, $J = 8.4, 4.3$ Hz, -CHCHaHbCOO-), 4.45 (1H, dd, $J = 8.4, 8.2$ Hz, -CHCHaHbCOO-), 5.88 (1H, s, H-1), 5.93 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 5.95 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 6.50 (2H, s, Ar-H-2'), 6.53 (1H, s, H-8), 6.62 (1H, s, H-5); ^{13}C -NMR (CDCl_3) δ 34.2 (t), 54.6 (d), 56.1 (q), 59.7 (d), 60.8(q), 68.3 (d), 101.3 (t), 104.7 (d), 108.0 (d), 108.6 (d), 124.2 (s), 130.0 (s), 137.5 (s), 138.0 (s), 146.8 (s), 147.2 (s), 153.2 (s), 156.8 (s); HRMS m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_1\text{O}_7$ (M^+) 369.1218, found 399.1317.

= 1.4 Hz, -OCHaHbO-), 6.45 (1H, s, H-8), 6.63 (1H, s, H-5), 6.60 (1H, dd, $J = 8.2, 2.1$ Hz, H-6'), 6.77 (1H, d, $J = 8.2$ Hz, H-5'), 6.93 (1H, d, $J = 2.1$ Hz, H-2'); $^{13}\text{C-NMR}$ (CDCl_3) δ 34.7 (t), 47.9 (d), 55.9 (q), 56.0 (q), 56.03 (d), 68.4 (t), 101.1 (t), 108.26 (d), 108.35 (d), 110.8 (d), 112.0 (d), 120.6 (d), 125.6 (s), 127.0 (s), 134.6 (s), 146.7 (s), 147.0 (s), 148.8 (s), 149.1 (s), 156.5 (s); HRMS m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_1\text{O}_6$ (M) $^+$ 369.1212, found 369.1214.

(1R,3R)-2-Azabursehernin 10b: Oil; $[\alpha]_{\text{D}}^{22} +21.9$ (c 0.03, CH_3Cl); IR (liquid film) ν_{max} 1757 (C=O), 1478 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.95 (1H, dd, $J = 14.6, 3.4$ Hz, 4-Hb), 3.01 (1H, dd, $J = 14.6, 10.3$ Hz, 4-Ha), 3.83 (3H, s, Ar-OCH₃), 3.84 (3H, s, Ar-OCH₃), 4.03 (1H, ddd, $J = 10.8, 7.9$ Hz, -CHCHaHbCOO-), 4.11 (1H, m, H-3), 4.54 (1H, dd, $J = 7.9, 6.9$ Hz, -CHCHaHbCOO-), 5.30 (1H, s, H-1), 5.88 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 5.92 (1H, d, $J = 1.4$ Hz, -OCHaHbO-), 6.50 (1H, s, H-8), 6.62 (1H, s, H-5), 6.67 (1H, d, $J = 8.2$ Hz, H-5'), 6.80 (1H, d, $J = 2.0$ Hz, H-2'), 6.84 (1H, dd, $J = 8.2, 2.0$ Hz, H-6'); HRMS m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_1\text{O}_6$ (M) $^+$ 369.1212, found 369.1205. *Satisfied signals could not be obtained in the $^{13}\text{C-NMR}$ spectrum since of shortage of material.

(1S,3R)-10c: Colorless crystals: mp 203–206 °C; $[\alpha]_{\text{D}}^{22} +181.9$ (c 0.18, CH_3Cl); IR (KBr) ν_{max} 1762 (C=O), 1502 (C=C), 1487 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.85 (1H, dd, $J = 15.5, 5.2$ Hz, H-4_A), 2.89 (1H, br dd, $J = 15.5, 10.3$ Hz, H-4_B), 3.73 (3H, s, Ar-OCH₃), 3.75 (3H, s, Ar-OCH₃), 4.11 (1H, dd, $J = 8.5, 3.0$ Hz, -CHCHaHbCOO-), 4.18 (1H, m, H-3), 4.44 (1H, dd, $J = 8.5, 7.8$ Hz, -CHCHaHbCOO-), 5.90 (2H, s, -OCH₂O-), 6.14 (1H, s, H-1), 6.38 (1H, s, H-8), 6.60 (1H, s, H-5), 6.63 (1H, d, $J = 3.0$ Hz, H-2'), 6.80 (1H, dd, $J = 8.7, 3.0$ Hz, H-6'), 6.86 (1H, d, $J = 8.7$ Hz, H-5'); $^{13}\text{C-NMR}$ (CDCl_3) δ 34.2 (t), 49.3 (d), 52.2 (d), 55.7 (q), 56.5 (q), 68.0 (t), 101.0 (t), 107.5 (d), 108.4 (d), 112.7 (d x 2), 116.8 (d), 125.3 (s), 128.1 (s), 131.8 (s), 146.6 (s), 146.7 (s), 151.5 (s), 153.4 (s), 156.7 (s); HRMS m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_1\text{O}_6$ (M) $^+$ 369.1212, found 369.1209.

(1S,3R)-2-Azapolygamain 11a: Colorless needles: mp 165–167 °C; $[\alpha]_{\text{D}}^{25} +150.6$ (c 1.28, CH_3Cl); IR (KBr) ν_{max} 1742 (C=O), 1590, 1517, 1501, 1483 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.86 (1H, dd, $J = 15.5, 10.5$ Hz, 4-Hb), 2.91 (1H, dd, $J = 15.5, 5.0$ Hz, 4-Ha), 4.03 (1H, dddd, $J = 10.5, 8.3, 5.0, 4.3$ Hz, H-3), 4.09 (1H, dd, $J = 8.7, 4.3$ Hz, -CHCHaHbCOO-), 4.45 (1H, dd, $J = 8.7, 8.3$ Hz, -CHCHaHbCOO-), 5.83 (1H, s, H-1), 5.92 (1H, d, $J = 1.4$ Hz, -OCHHO-), 5.93 (2H, d, $J = 1.4$ Hz, -OCHHO-), 5.94 (1H, d, $J = 1.4$ Hz, -OCHHO-), 6.42 (1H, s, H-8), 6.61 (1H, s, H-5), 6.71 (1H, d, $J = 1.8$ Hz, H-2'), 6.75 (1H, d, $J = 8.0$ Hz, H-5'), 6.78 (1H, dd, $J = 8.0, 1.8$ Hz, H-6'); $^{13}\text{C-NMR}$ (CDCl_3) δ 34.3 (t), 47.9 (d), 56.0 (d), 68.4 (t), 101.13 (t), 101.15 (t), 108.1 (d), 108.2 (d), 108.3 (d), 108.8 (d), 122.2 (d), 125.5 (s), 127.0 (s), 135.9 (s), 146.8 (s), 147.1 (s), 147.3 (s), 147.8 (s), 156.4 (s); HRMS m/z calcd for $\text{C}_{19}\text{H}_{15}\text{N}_1\text{O}_6$ (M) $^+$ 353.0899, found 353.0894.

(1R,3R)-2-Azapolygamain 11b: Oil; $[\alpha]_{\text{D}}^{25} +66.1$ (c 0.03, CH_3Cl); IR (liquid film) ν_{max} 1757 (C=O),

1511, 1487 (C=C) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 2.95 (1H, dd, $J = 14.8, 3.4$ Hz, 4-Hb), 3.01 (1H, dd, $J = 14.8, 10.4$ Hz, 4-Ha), 4.03 (1H, dd, $J = 10.8, 7.6$ Hz, -CHCHaHbCOO-), 4.10 (1H, dddd, $J = 10.8, 10.4, 6.7, 3.4$ Hz, H-3), 4.54 (1H, dd, $J = 7.6, 6.7$ Hz, -CHCHaHbCOO-), 5.48 (1H, s, H-1), 5.87 (1H, d, $J = 1.4$ Hz, -OCHHO-), 5.90 (1H, d, $J = 1.6$ Hz, -OCHHO-), 5.91 (1H, d, $J = 1.6$ Hz, -OCHHO-), 5.92 (1H, d, $J = 1.4$ Hz, -OCHHO-), 6.48 (1H, s, H-8), 6.60 (1H, s, H-5), 6.66 (1H, d, $J = 1.6$ Hz, H-2'), 6.74 (1H, d, $J = 7.6$ Hz, H-5'), 6.86 (1H, dd, $J = 7.6, 1.6$ Hz, H-6'); $^{13}\text{C-NMR}$ (CDCl_3) δ 34.2 (t), 54.4 (d), 59.3 (d), 68.2 (t), 101.1 (t), 101.3 (t), 108.5 (d), 108.0 (d), 108.1 (d), 108.5 (d), 121.5 (d), 124.1 (s), 130.0 (s), 136.4 (s), 146.8 (s), 147.0 (s), 147.2 (s), 147.8 (s), 156.8 (s); HRMS m/z calcd for $\text{C}_{19}\text{H}_{15}\text{N}_1\text{O}_6$ (M^+) 353.0899, found 353.0903.

Cytotoxic Activity Assay⁴²

All stock cultures were grown in T-25 flask. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 1500-7500 cells per well with compounds added from DMSO-diluted stock. After 3 days in culture, attached cells were fixed with cold trichloroacetic acid and then stained with 0.4% sulforhodamine B. The absorbency at 562 nm was measured using a microplate reader after solubilizing the bound dye. The mean ED_{50} is the concentration of agent that reduces cell grows by 50% under the experimental conditions and is the average of two independent determinations that were reproducible and statistically significant. The following human tumor cell lines were used in the assay: A549 (human lung carcinoma), HCT-8 (colon adenocarcinoma), and MCF-7 (breast cancer). All cell lines were obtained from the Lineberger Cancer Center (UNC-CH) or ATCC (Rockville, MD) and were cultured in RPMI-1640 medium supplemented with 25 mM HEPES, 0.25% sodium bicarbonate, 10% fetal bovine serum, and 100 $\mu\text{g}/\text{mL}$ kanamycin.

ACKNOWLEDGEMENTS

We are grateful to Dr. K. Minoura, Ms. M. Fujitake and Ms. S. Seki of this University for NMR, MS measurements, and elemental analysis respectively. This work was supported in part by a Grant-in-Aid for "High-Tech Research Center" Project for Private Universities: matching fund subsidy from MEXT Ministry of Education, Culture, Sports, Science, and Technology; 2002–2006, Japan (M. Arimoto) and in part by NIH grant CA 17625 (K. H. Lee).

This paper is dedicated to the memory of late Honorary Professor Hideo Yamaguchi of Osaka University of Pharmaceutical Sciences, who passed away on 22nd January 2009.

REFERENCES

1. M. Saleem, H. J. Kim, M. S. Ali, and Y. S. Lee, *Nat. Prod. Rep.*, 2005, **22**, 696.
2. C. Canel, R. M. Moraes, F. E. Dayan, and D. Ferreira, *Phytochemistry*, 2000, **54**, 115.

3. J. C. Paulson and W. O. McClure, *Annals of the New York Academy of Sciences*, 1975, **253** (Biol. Cytoplasmic Microtubules, Pap. Conf., 1974), 517.
4. E. L. Baldwin and N. Osheroff, [Current Medicinal Chemistry: Anti-Cancer Agents](#), 2005, **5**, 363.
5. V. Srivastava, A. S. Negi, J. K. Kumar, M. M. Gupta, and S. P. S. Khanuja, [Bioorg. Med. Chem.](#), 2005, **13**, 5892.
6. Z. Xiao, J. R. Vance, K. F. Bastow, A. Brossi, H. K. Wang, and K. H. Lee, [Bioorg. Med. Chem.](#), 2004, **12**, 3363.
7. M. Arimoto, H. Yamaguchi, and S. Nishibe, *Studies in Natural Products Chemistry*, 1996, **18** (Stereoselective Synthesis (Part K)), 551.
8. M. Arimoto, S. Matsuura, C. Muro, H. Tsujibo, E. Matsumura, H. Yamaguchi, and Y. Inamori, [Biosci. Biotech. Biochem.](#), 1994, **58**, 189.
9. M. Tanoguchi, E. Hosono, M. Kitaoka, M. Arimoto, and H. Yamaguchi, [Chem. Pharm. Bull.](#), 1991, **39**, 1873.
10. M. Arimoto, A. Miyamoto, H. Nakayama, T. Okano, H. Miyoshi, A. Iwai, M. Yamanaka, F. Hirano, A. Ohguro, H. Ichikawa, and Y. Usami, *Bull. Osaka Univ. Pharm. Sci.*, 2009, **3**, 39.
11. S. Tu, Y. Zhang, B. Jiang, R. Jia, J. Zhang, J. Zhang, and S. Ji, [Synthesis](#), 2006, **22**, 3874.
12. Y. Hitotsuyanagi, M. Fukuyo, K. Tsuda, M. Kobayashi, A. Ozeki, H. Itokawa, and K. Takeya, [Bioorg. Med. Chem. Lett.](#), 2000, **10**, 315.
13. A. Legrand, B. Rigo, P. Gautret, J.-P. Henichart, and D. Couturier, [J. Heterocycl. Chem.](#), 1999, **36**, 1263.
14. R. Katritzky, J. Cobo-Domingo, B. Yang, and P. J. Steel, [Tetrahedron: Asymmetry](#), 1999, **10**, 255.
15. Y. Hitotsuyanagi, M. Kobayashi, K. Takeya, and H. Itokawa, [J. Chem. Soc., Perkin Trans. 1](#), 1995, **11**, 1387.
16. Y. Hitotsuyanagi, Y. Ichihara, K. Takeya, and H. Itokawa, [Tetrahedron Lett.](#), 1994, **35**, 9401.
17. P. Lienard, J. C. Quirion, and H. P. Husson, [Tetrahedron](#), 1993, **49**, 3995.
18. H. L. Pearce, N. J. Bach, and T. L. Cramer, [Tetrahedron Lett.](#), 1989, **30**, 907.
19. J. Van der Eycken, J. P. Bosmans, D. Van Haver, M. Vandewalle, A. Hulkenberg, W. Veerman, and R. Nieuwenhuizen, [Tetrahedron Lett.](#), 1989, **30**, 3873.
20. J. P. Bosmans, J. Van der Eycken, M. Vandewalle, A. Hulkenberg, R. Van Hes, and W. Veerman, [Tetrahedron Lett.](#), 1989, **30**, 3877.
21. K. Tomioka, Y. Kubota, and K. Koga, [Tetrahedron Lett.](#), 1989, **30**, 2953.
22. K. Tomioka, Y. Kubota, and K. Koga, [Tetrahedron](#), 1993, **49**, 1891.
23. Aida, M. Kano, Y. Kubota, and K. Koga, and K. Tomioka, [Bioorg. Med. Chem. Lett.](#), 1997, **7**, 2565.
24. Aida, M. Kano, Y. Kubota, and K. Koga, and K. Tomioka, [Chem. Pharm. Bull.](#), 2000, **48**, 486.

25. H. Itokawa, Y. Hitotsuyanagi, and K. Takeya, [*Heterocycles*, 1992, **33**, 537.](#)
26. S. Yamada, T. Fujii, and T. Shioiri, [*Chem. Pharm. Bull.*, 1962, **10**, 680.](#)
27. E. Marnantoni, M. Petrini, and R. Profeta, [*Tetrahedron Lett.*, 2004, **45**, 2133.](#)
28. U. Schöllkopf, U. Groth, and C. Deng, [*Angew. Chem., Int. Ed. Engl.*, 1981, **20**, 798.](#)
29. P. B. McDoniel and J. R. Cole, [*J. Pharm. Sci.*, 1972, **61**, 1992.](#)
30. H. Yamaguchi, M. Arimoto, K. Yamamoto, and A. Numata, *Yakugaku Zasshi*, 1979, **99**, 674.
31. H. Yamaguchi, M. Arimoto, M. Tanoguchi, T. Ishida, and M. Inoue, [*Chem. Pharm. Bull.*, 1982, **30**, 3212.](#)
32. P. Richomme, J. Bruneton, P. Cabalion, and M. M. Debray, [*J. Nat. Prod.*, 1984, **47**, 879.](#)
33. M. C. Chalandre, C. Pareyre, and J. Bruneton, *Annal. Pharm. Francaises*, 1984, **42**, 317.
34. Koulman, M. E. Kubbinga, S. Batterman, H. J. Woerdenbag, N. Pras, J. G. Woolley, and W. J. Quax, [*Planta Med.*, 2003, **69**, 733.](#)
35. G. C. Hokanson, [*J. Nat. Prod.*, 1979, **40**, 378.](#)
36. G. J. Provan and P. G. Waterman, [*Planta Med.*, 1985, 271.](#)
37. B. Gözler, T. Gözler, G. Saglam, and M. Hesse, [*Phytochemistry*, 1996, **42**, 689.](#)
38. L. Ollelo, L. Castero, and D. Dominguez, [*Tetrahedron*, 1999, **55**, 4445.](#)
39. G. Guillena and C. C. Nájera, [*J. Org. Chem.*, 2000, **65**, 7310.](#)
40. Y. N. Belokon, N. B. Bespalova, T. D. Churkina, I. Cisařová, M. G. Ezernitskaya, S. R. Harutyunyan, R. Hrdina, H. B. Kagan, P. Kočovský, K. A. Kochetkov, O. V. Larionov, K. A. Lyssenko, M. North, M. Polášek, A. S. Peregudov, V. V. Prisyazhnyuk, and Š. Vyskočil, [*J. Am. Chem. Soc.*, 2003, **125**, 12680.](#)
41. V. Deulofeu and J. Mendive, *Z. Physiol. Chem.*, 1932, **211**, 1.
42. Y. Nakanishi, F.-R. Chang, C.-C. Liaw, Y.-C. Wu, K. F. Bastow, and K.-H. Lee, [*J. Med. Chem.*, 2003, **46**, 3185.](#)